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Cells possess an armamentarium of DNA repair pathways to counter DNA damage and
prevent mutation. Here we use C. elegans whole genome sequencing to systematically
quantify the contributions of these factors to mutational signatures. We analyse 2,717 gen-
omes from wild-type and 53 DNA repair defective backgrounds, exposed to 11 genotoxins,
including UV-B and ionizing radiation, alkylating compounds, aristolochic acid, aflatoxin B1,
and cisplatin. Combined genotoxic exposure and DNA repair deficiency alters mutation rates
or signatures in 41% of experiments, revealing how different DNA alterations induced by the
same genotoxin are mended by separate repair pathways. Error-prone translesion synthesis
causes the majority of genotoxin-induced base substitutions, but averts larger deletions.
Nucleotide excision repair prevents up to 99% of point mutations, almost uniformly across
the mutation spectrum. Our data show that mutational signatures are joint products of DNA
damage and repair and suggest that multiple factors underlie signatures observed in cancer
genomes.
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A cell’s DNA is constantly altered by a multitude of gen-otoxic stresses including environmental toxins andradiation, DNA replication errors and endogenous
metabolites, all rendering the maintenance of the genome a
titanic challenge. Organisms thus evolved diverse DNA repair
mechanisms to detect and mend DNA damage, and to eliminate
or permanently halt the progression of genetically compromised
cells. Nevertheless, some DNA lesions escape detection and repair
or are processed by error-prone pathways, leading to mutagenesis
—the process that drives evolution but also inheritable disease,
ageing and cancer.
The multifaceted nature of mutagenesis results in distinct
mutational spectra, characterised by the specific distribution of
single- and multi-nucleotide variants (SNVs and MNVs), small
insertions and deletions (indels), large structural variants (SVs),
and copy number alterations. Studying mutational patterns yields
insights into the nature of DNA damage and DNA repair pro-
cesses. Indeed, the analysis of thousands of cancer genomes and
exomes led to the discovery of more than 50 mutational signatures
of base substitutions1,2. Some of these signatures, deduced by
computational pattern recognition, have evident associations with
exposure to known mutagens such as UV light, tobacco smoke,
the food contaminants aristolochic acid (AA) and aflatoxins3–5, or
with DNA repair deficiency syndromes and compromised DNA
replication1,6,7. However, the aetiology of many computationally
extracted cancer signatures still has to be established.
The association between mutational spectra and their under-
lying mutagenic processes is complicated as mutations arise from
various DNA lesions, which are mended by numerous and par-
tially redundant DNA repair pathways. Hence, there are at least
two unknowns that contribute to a mutational spectrum: DNA
damage and DNA repair. The fact that these counteracting pro-
cesses are jointly shaping mutagenesis is perhaps best exemplified
at the interplay of nucleotide misincorporation by replicative
DNA polymerases and mismatch repair (MMR). MMR operates
downstream of the replication fork and mends many mismatches
caused by misincorporated nucleotides, often in a base-specific
way. Thus, when polymerase fidelity is compromised, MMR
provides a backstop and observed mutations stem from the subset
of lesions that escaped MMR or were incorrectly repaired; the full
spectrum of replication errors only becomes visible under MMR
deficiency. Indeed, distinct mutational signatures have been
observed in human cancers with concomitant POLE exonuclease
mutations and MMR deficiency8 and also in Caenorhabditis ele-
gans lines deficient for both the MMR factor pms-2 and the
polymerase epsilon subunit pole-49.
Here, we experimentally investigate the counteracting roles of
genotoxic processes and DNA repair. Using C. elegans whole-
genome sequencing, we determined mutational spectra resulting
from the exposure of wild-type and 53 DNA repair defective lines,
encompassing most conserved DNA repair and DNA damage
response pathways, to 11 genotoxic agents causing a diverse set of
DNA alterations. Combining genotoxin exposure and DNA
repair deficiency in many cases led to altered mutagenesis, sig-
nified by either higher or lower mutation rates or altered muta-
tion spectra compared to DNA repair deficiency or wild-type
genotoxin exposure alone. These interactions highlight how dif-
ferent DNA lesions induced by the same genotoxin are processed
by a number of DNA repair pathways, often specific for a par-
ticular type of DNA damage, therefore changing mutation spectra
usually in subtle but sometimes also dramatic ways. We confirm
that similar interactions are also imprinted in cancer genomes
and provide an explanation why such signatures are difficult to
detect. Our data imply that mutational signatures derived from
cancer genomes can be variable, and may not have a one-to-one
relationship to distinct mutagenic processes.
Results
Experimental mutagenesis in C. elegans. To determine how the
interplay between mutagenic processes and DNA repair status
impacts mutational spectra, we used 54 C. elegans strains,
including wild-type and 53 DNA repair and DNA damage sen-
sing mutants (Fig. 1a). These cover all major DNA repair path-
ways including direct damage reversal (DR), base excision repair
(BER), nucleotide excision repair (NER), MMR, DNA double-
strand break repair (DSBR), translesion synthesis (TLS), DNA
crosslink repair (CLR), and DNA damage sensing checkpoints
(DS)10–14 (see Supplementary Table 1 for a full list). To inflict
different types of DNA damage we used 12 genotoxic agents
encompassing UV-B, X- and γ-radiation; the alkylating agents
ethyl methanesulfonate (EMS), dimethyl sulfate (DMS) and
methyl methanesulfonate (MMS); AA and aflatoxin B1, which
form bulky DNA adducts; hydroxyurea as a replication fork
stalling agent; and cisplatin, mechlorethamine (nitrogen mustard)
and mitomycin C (which was only used in the wild-type) known
to form DNA intra- and inter-strand crosslinks.
To investigate the level of mutagenesis for each genotype in the
absence of exogenous mutagens, we clonally propagated wild-type
and DNA repair defective C. elegans lines over 5–40 generations
in mutation accumulation experiments (Methods, Fig. 1a)9,15. In
addition, to measure the effects of genotoxic agents, nematodes
were exposed to mutagenize germ cells and mutational spectra
were analysed by sequencing clonally derived progeny15. Self-
fertilising propagation through single zygotes provides clonally
amplified DNA for subsequent whole-genome sequencing
(Fig. 1a). Experiments were typically performed in triplicates,
with dose escalation for genotoxin treatments.
Overall, we analysed a total of 2717 C. elegans genomes
comprising 477 samples from mutation accumulation experi-
ments, 234 samples from genotoxin-treated DNA repair profi-
cient wild-type lines and 2006 samples from interaction
experiments combining genotoxin treatment with DNA repair
deficiency. The sample set harboured a total of 162,820 acquired
mutations (average of ~60 mutations per sample) comprising
135,348 SNVs, 937 MNVs, 24,308 indels and 2,227 SVs.
Attribution of observed mutations to each genotoxin, to distinct
DNA repair deficiencies, and to their combined action was done
using a negative binomial regression analysis leveraging the
explicit knowledge of genotoxin dose, genotype, and the number
of generations across all samples to obtain absolute mutation
rates and signatures, measured in units of mutations/generation/
dose (Methods).
Mutation accumulation under DNA repair deficiencies. Com-
paring mutations in genomes of the first and final generations for
the 477 mutation accumulation samples, we observed a generally
low rate of mutagenesis in the range of 0.8–2 mutations per
generation similar to previous reports on 17 DNA repair deficient
C. elegans strains15,16 (Supplementary Note 1). Notable excep-
tions were lines carrying knockouts of genes affecting MMR,
DSBR and TLS (Fig. 1c, Supplementary Note 1). MMR deficient
mlh-1 knockouts manifested in high base substitution rates
combined with a pattern of 1 bp insertions and deletions at
homopolymer repeats, similar to reports in human cancers
(cosine similarity c= 0.85)9,17. DSBR deficient strains carrying a
deletion in brc-1, the C. elegans ortholog of the BRCA1 tumour
suppressor, exhibited a uniform base substitution spectrum and
increased rate of small deletions and tandem duplications
(Fig. 1c), features also observed in BRCA1 defective cancer gen-
omes (c= 0.69 relative to SBS3)18. TLS polymerase knockouts of
polh-1 and rev-3 yielded a mutational spectrum dominated by
50–400 bp deletions. We postulate that these deletions arise when
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replication over damaged bases is stalled or fails19–21 (Fig. 1c,
Supplementary Note 1). Furthermore, him-6 mutants, defective
for the C. elegans orthologue of the BLM (Bloom syndrome)
helicase, and smc-6 mutants, defective for the Smc5/6 cohesin-like
complex, showed an increased incidence of SVs (Fig. 1c).
Experimentally derived mutational signatures for all 54 genetic
backgrounds are summarised in Supplementary Note 1 and
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Fig. 1 Experimental study design and data overview. a Left: C. elegans wild-type (WT) and mutants of selected genes from the indicated DNA repair
pathways were propagated over several generations or exposed to increasing doses of 12 different genotoxins. Genomic DNA from samples before and after
propagation or without and with treatment was sequenced to determine mutational spectra (Methods). Right: representative experimental mutational
spectra across 119 mutation classes: 96 single base substitutions classified by the 6 possible base changes in their ‘5 and 3’ base context, di- and multi-
nucleotide variants (MNV), 6 classes of deletions of different length and context, 2 classes of complex indels, 6 classes of insertions and 7 classes of
structural variants (see panel d for the list of mutation classes). Individual bars represent the average number of mutations observed per mutation class.
b 2D t-SNE representation of all C. elegans samples based on the cosine similarity between mutational profiles. Dots represent individual sequenced samples,
with dot sizes proportional to the number of observed mutations. Colours depict genotoxin exposures, mutation accumulation samples are not couloured.
Black boxes highlight selected genotoxins and DNA repair deficiencies. c Experimental mutational signatures of selected DNA repair deficiencies. Each bar
corresponds to the estimated mean number of mutations of a particular mutation class per propagated generation. Error bars denote 95% credible intervals.
See panel d for the list of mutation classes. d Experimental mutational signatures of selected genotoxin exposures in wild-type C. elegans. Each bar
corresponds to the estimated mean number of mutations of a particular mutation class per generation per dose. Error bars denote 95% credible intervals.
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data from human cancers, which exhibit hypermutation for
deficiency of MMR, POLE exonuclease domain, and DSBR1, but
barely for extremely common monoallelic or rarely occurring
biallelic mutations in other DNA repair genes (Supplementary
Fig. 1, Supplementary Note 3, Supplementary Data 3).
Mutagenesis under genotoxic exposures. Genotoxins tended to
have a stronger influence on the mutational spectrum compared
to DNA repair deficient backgrounds (Fig. 1b; see Supplementary
Fig. 2 and Supplementary Data 2 for a full list of spectra). The
methylating agents MMS and DMS, produced very similar
mutation spectra with high numbers of T > A and T > C sub-
stitutions (Fig. 1b, d).
Samples treated with the ethylating agent EMS were char-
acterised by C > T mutations, somewhat similar to the mutational
signature SBS11 observed in cancer genomes, which has been
attributed to exposure to the alkylating agent temozolomide
(cosine similarity c= 0.91)2. However, both signatures differ from
the EMS spectrum reported in human iPS cells22 (Supplementary
Fig. 2b), likely due to differential repair capacity.
Bulky adducts created by AA and aflatoxin B1 exposure resulted
in mutational spectra with typical T > A and C >A mutations,
respectively, similar to those observed in exposed human cancers
and cell lines (c= 0.95 and c= 0.92, respectively)4,23. UV-B
radiation induced characteristic C > T transitions in a YpCpH
context (Y=C/T; H=A/C/T), similar to SBS7a/b (c= 0.95 for C >
T alone), but with an unexpected rate of T > A transversions in a
WpTpA context (W=A/T; c= 0.69 for all variants), which might
be caused by the higher proportion of 6-4 photoproducts induced
by UV-B compared to sunlight and possibly lower repair efficiency
of these lesions in C. elegans24. Ionizing radiation (X- and ɣ-rays)
caused single and multi-nucleotide substitutions, but also deletions
and SVs, in agreement with the spectra of radiation-induced
secondary malignancies25 (c= 0.89 for substitution spectra). Lastly,
cisplatin exposure induced C >A transversions in a CpCpC and
CpCpG context, deletions, and SVs in agreement with previous
studies (Fig. 1b, d)15,22,26,27. Interestingly, the overall cisplatin-
induced mutation spectrum seems strongly organism-specific
(Supplementary Methods).
The general resemblance of genotoxin-derived mutational
signatures across organisms (Supplementary Fig. 2, Supplemen-
tary Methods) reflects the high level of conservation of DNA
repair pathways among eukaryotes. Interestingly, discrepancies
observed between species or different cell lines derived from the
same species may provide insights into differences in genotoxin
metabolism or DNA repair capacity.
Signatures of concomitant DNA damage and repair deficiency.
The experimentally controlled exposure time and doses enabled
us to quantify how strongly a DNA repair deficiency altered
mutational effects of a genotoxin on a genome-wide scale. We
considered a DNA repair deficiency and a genotoxin as inter-
acting if the mutation rate of all or a type of mutations (e.g.
substitutions, indels or SVs) changed relative to the expectation
that the observed mutations can be expressed as the sum of the
genotoxin spectrum in wild-type and the DNA repair deficiency
spectrum without genotoxin exposure (Methods).
Genotoxin-repair deficiency interactions were very common:
In total, 88/196 (41%, at false-discovery rate (FDR) < 5%) of the
combinations we tested displayed an interaction between DNA
repair status and genotoxin treatment involving 9/11 genotoxins
and 32/53 genotypes (Fig. 2, for a comprehensive list of effects see
Supplementary Note 2 and Supplementary Data 4). Most
frequently interactions increased the numbers of mutations
obtained for a given dose of mutagen, with the strongest increase
of 50x observed in polk-1 mutants under exposure to alkylating
agents (Fig. 2a). Conversely, knockouts of TLS polymerases REV-
3 and to a lower extent POLH-1 reduced the rate of point
mutations for a range of genotoxins while showing increased
numbers of indels and/or SVs (Fig. 2a). While some interactions
left the mutational spectrum largely unchanged, such as MMS-
exposure of xpc-1 mutants, others, such as MMS- or DMS-
exposure of polk-1 mutants, had a profound impact on
mutational spectra, indicating that this specific DNA repair
pathway only mends a subset of lesions introduced by the
genotoxin (Fig. 2b).
Overall, we estimate that of the 141,004 mutations observed in
genotoxin exposure experiments in DNA repair deficient strains,
26% were attributed to the endogenous mutagenicity of DNA
repair deficiency independent of genotoxic exposure and 54%
were attributed to genotoxic exposures independent of the genetic
background. In addition, 23% of mutations arose due to positive
interactions between mutagen exposure and DNA repair
deficiency leading to increased mutagenicity (Fig. 2c). Finally,
we found that 3% of mutations were prevented by negative
interactions between genotoxins and DNA repair deficiency
leading to reduced mutagenesis.
Applying a similar approach to a range of DNA repair deficient
and proficient cancers with suspected genotoxic exposures, we
were able to characterise several cases of DNA damage-repair
interactions leading to increased mutagenesis and/or altered
signatures, such as POLEEXO and MMR, tissue-specific changes
of the MMR deficiency signature, UV damage and NER, or
APOBEC-induced mutagenesis and TLS (Fig. 2d, Supplementary
Fig. 3, Supplementary Note 4). However, we found that
interactions were hard to detect due to the unknown history of
exposure and DNA repair defects, and detectable effects were
typically only moderate.
Lesion-specific repair and mutagenicity of DNA alkylation.
Many genotoxins, such as the alkylating agent MMS, inflict DNA
damage on different nucleotides and residues thereof (Fig. 3a).
MMS induces several different base methylations, including non-
mutagenic N7-meG, as well as mutagenic N3-meA and O6-
meG28, which, taken together, produced a mutation rate of
approximately 230 mutations/mM/generation in C. elegans wild-
type (Fig. 3a). However, the underlying mutagenic and repair
mechanisms for these DNA adducts are very different: O6-meG is
subject to direct reversal by alkyl-guanine DNA alkyltransferases
and tends to pair with thymine29, whereas N3-meA can be
mended by BER or NER30,31. If unrepaired, N3-meA requires
TLS polymerases for lesion bypass during replication, which can
be error-free or result in the misincorporation of A or C opposite
N3-meA32.
Indeed, our analysis showed diverse changes in the MMS-
induced signature across DNA repair deficient backgrounds. In
the absence of NER, the mutation rate of adenine was elevated
1.5× in xpc-1 mutants and 3× in xpf-1 and xpa-1 mutants without
a change in the mutational signature (Fig. 2a, b, Supplementary
Fig. 4a), indicating that an increased proportion of N3-meA
underwent error-prone TLS. These fold changes (FCs) corre-
spond to about 30% and 60% of mutations being prevented by
error-free XPC-1 and XPF-1/XPA-1 repair activity, respectively
(Fig. 3c). A similar trend of 1.5–3-fold increase in T >M
mutations was observed for EMS exposure under NER deficiency
(Supplementary Fig. 4b). In contrast to MMS, EMS mostly
induces O6-etG lesions with a small amount of N3-etA29.
Consistent with this, we estimate that NER prevents about
25–40% of mutations upon EMS exposure (Supplementary
Fig. 4c).
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Deficiency of polymerase κ increased the overall mutation
rate upon MMS treatment 17× with approximately 3,800
mutations/mM/generation (Fig. 3b). In line with the role of
TLS in bypassing N3-meA during replication, polymerase κ
deficiency yielded an approximately 10–100× higher rate of
T > M (M= A/C) mutations, especially in TpTpN and CpTpN
contexts (Fig. 3b). This increase also coincided with a distinct
change in the mutational spectrum marked by a highly
increased proportion of T > A transversions in a TpTpT context
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Fig. 2 Widespread and diverse genotoxin-repair interactions in C. elegans and cancer. a Estimated fold changes between observed numbers relative to
expected numbers of mutations based on additive genotoxin and DNA repair deficiency effects shown for base substitutions (upper panel), insertions/
deletions (middle panel), and structural variants (lower panel) for all genotoxins. AFL - aflatoxin B1, CIS - cisplatin, HU - hydroxyurea, ME -
mechlorethamine. A value of 1 indicates no change. Black lines denote point estimates. Interactions with fold changes significantly above or below 1 (as per
testing whether the squared log ratio between mutation numbers induced by a genotoxin in mutants versus wild-type follows the χ2 distribution at 5%
FDR) are shown as dark grey, the rest as light grey bars with their width indicating confidence interval. b Changes in spectra of genotoxin-induced
mutations. Black lines denote point estimates. Interactions with cosine distances larger than 0.2 are shown with dark blue confidence intervals, others are
shown in light blue. c Numbers of mutations attributed to genotoxins (blue) and DNA repair deficiencies (green), as well as positive interactions (pink) and
negative interactions (orange) between genotoxins and DNA repair deficiencies. d Summary of interaction effects between selected DNA repair pathway
deficiencies and DNA damage-associated mutational signatures in human cancers. Left: Changes in age-adjusted mutation burden. Right: Change in
mutational signatures. Black lines denote the average values and bars correspond to 95% confidence intervals. Significant interactions are shown in darker
colour (as per testing whether the squared log ratio between mutation numbers expected in deficient versus proficient samples follows the χ2 distribution
at 5% FDR, or whether the cosine similarity between the spectra is lower than 0.8).
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error-free and prevents 90–99% of DNA adducts caused by
MMS exposure from becoming mutagenic (Fig. 3c). A similar
increase of T > M substitutions (at the rate of 10×) was observed
in Pol κ deficient mutants upon treatment with EMS,
corresponding to 50% of EMS-induced mutations being
prevented by POLK-1 mediated error-free TLS (Supplementary
Fig. 4b, c). We postulate that in the absence of Pol κ, the bypass
of alkylated adenines has to be achieved by other, error-prone
TLS polymerases, leading to increased T > M mutagenesis,
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One of the candidates for this error-prone TLS is rev-3, which
encodes the catalytic subunit of TLS Pol ζ. In contrast to polk-1
TLS deficiency where the mutation rate was increased, the
knockout of rev-3/Pol ζ partially suppressed MMS-induced base
substitutions but increased the number of small deletions
(Fig. 3b), indicating that Pol ζ is an essential component for the
bypass of alkylated bases. We estimated that about 60% of MMS-
induced mutations in wild-type result from error-prone repair
synthesis conferred by Pol ζ (Fig. 3c).
Combining MMS exposure with alkyl-transferase agt-1 defi-
ciency also led to a striking change in the MMS signature,
increasing the C > T mutation rate from about 15 mutations/mM
in the wild-type to over 200 in the mutant, while leaving the rate
of T >M mutations unchanged (Fig. 3b). This demonstrates that
AGT-1 specifically reverses most O6-methylguanine adducts in
an error free manner, thus acting as the functional C. elegans
ortholog of the human O6-methylguanine DNA methyltransfer-
ase MGMT. Thus, the repair activity of AGT-1 prevents 50% of
mutations which would otherwise be induced by MMS (Fig. 3c).
A similar, but weaker effect of agt-1 deficiency was observed upon
exposure to the ethylating agent EMS, leading to a 1.5-
fold increase in C > T transitions, indicating that AGT-1 is also
involved in, but less efficient at, removing ethyl groups, the latter
result being consistent with reports measuring single locus
reversion rates in E. coli33 (Supplementary Fig. 4b, c).
An even stronger interaction, which has already been
therapeutically exploited, occurs between the human agt-1
ortholog MGMT and temozolomide, a DNA alkylating che-
motherapeutic, in temozolomide-treated glioblastomas (Fig. 3d)34.
This is in good agreement with our experimental findings that the
nature of mutation spectra detected upon EMS, DMS or MMS
alkylation depends on the status of agt-1 (Fig. 2a).
TLS causes the majority of substitutions. The contribution of
certain low-fidelity TLS polymerases to genotoxin-induced muta-
genesis is a wide-spread phenomenon35. Error-prone TLS is a key
mechanism used to tolerate and bypass several types of DNA
damage19,36, such as UV-induced cyclobutane pyrimidine dimers
which stall replicative polymerases. Removal of polymerase ζ was
shown to decrease the total frequency of mutations in yeast, mouse
and human cells37–39. In C. elegans, exposing wild-type to UV-B led
to approximately 10 mutations per 100 J m−2, comprised mostly of
C > T and T >C transitions (Supplementary Fig. 5a). Paradoxically,
the overall UV-B mutation rate was reduced 1.5-fold in rev-3/pol ζ
mutants, mostly through a reduction in base substitutions, which
was in contrast to a 4-fold increase of deletions longer than 50 bp
(Supplementary Fig. 5a). To protect the genome from such dele-
tions, which are likely to be deleterious, it is believed that TLS
bypasses UV lesions at the cost of a higher base substitution rate40.
Quantifying the amount of mutations resulting from the activity of
TLS polymerases REV-3/Pol ζ, POLH-1/Pol η and POLQ-1/Pol θ,
we observed that 60–80% of single base substitutions induced not
only by UV, but also by aflatoxin B1, AA, DMS and MMS could be
assigned to the activity of these polymerases (Fig. 4a, b). In contrast,
REV-3/Pol ζ and POLH-1/Pol η also prevented 40–80% of indels
and SVs following alkylating agents, UV and IR exposure (Fig. 4a).
In contrast to previous reports36,41,42, only very small genomic
interaction effects were observed in TLS mutants and cisplatin
exposure, which was comparably low in this screen due to high
lethality.
An inverse phenomenon is observed upon treating polq-1/Pol θ
deficient mutants with AA. Indels, in particular deletions between 50
and 400 bp in length, induced by AA in wild-type were nearly absent
in polq-1 deficient mutants (Fig. 4b). Hence, we estimate that
POLQ-1/Pol θ causes more than half of AA-induced indels and SVs
(Fig. 4a, b). Breakpoint analysis of AA-induced deletions derived
from all POLQ-1/Pol θ proficient lines demonstrated an excess of
single base matches, indicative of C. elegans POLQ-1/Pol θmediated
end-joining19,43 (Supplementary Fig. 5b, c, Supplementary Meth-
ods). We speculate that in the absence of POLQ-1/Pol θ, replication-
associated DSBs generated by persistent aristolactam adducts are
likely to be repaired by HR, a slower but less error-prone pathway44.
A noteworthy example illustrating the role of TLS polymerases
in cancer is conferred by APOBEC (apolipoprotein B mRNA
editing enzyme, catalytic polypeptide-like) and error-prone, TLS-
driven BER. APOBEC deaminates single-stranded cytosine to
uracil, which pairs with adenine during replication, leading to C
> T mutations. Uracil is thought to be removed by Uracil DNA
Glycosylase UNG; subsequent synthesis by error-prone TLS
REV1 leads to C > G mutations45,46. Indeed, a lack of C > G
mutations has been observed in a cancer cell line with UNG
silencing47. We found a relatively weak contribution of REV1 and
UNG mutation or silencing to APOBEC mutagenesis in human
cancers, which nevertheless confirms the expected trend: on
average, samples defective for REV1 or UNG display an 8%
decrease in C > G mutations (Fig. 4c). However, REV1 and UNG
status at diagnosis only explains a small fraction of APOBEC
mutations with low rates of C > G transversion, suggesting that
other processes contribute to these variants. Alternatively, the
underlying signature change may not be detectable due to REV1/
UNG mutation occurring late in cancer development compared
to APOBEC overactivation.
Fig. 3 DNA repair mutant specific MMS-induced mutational signatures. a DNA repair and mutagenicity of different DNA lesions induced by MMS:
chemical structures of non-mutagenic N7-methylguanine and mutagenic N3-methyladenine and O6-methylguanine are depicted. Methyl groups are
indicated in red. bMMS-induced signatures in wild-type, polk-1, rev-3 and agt-1 deficient C. elegans. Top: Mean estimates of MMS-induced mutation spectra
in wild-type and polk-1−/−. Error bars denote 95% credible intervals (CIs). Below: mutation rate fold changes per mutation class between the wild-type and
interaction spectra with 95% CIs. Point estimates for significant fold changes are shown in darker colour (credible intervals do not cross 1, red dotted line).
Centre: MMS-induced signature in rev-3−/− shown with respective fold changes. Bottom: MMS-induced signature in agt-1−/− shown with the respective
fold changes. Right: Number of mutations per replicate shown across MMS doses in wild-type (upper part), polk-1mutants (centre part), and agt-1 mutants
(lower part). c Estimated mean fractions of mutations contributed or prevented by different DNA repair components compared to the mutations observed
upon MMS exposure in wild-type. Bars with no fill colour reflect non-significant contributions (chi-squared test FDR 5% in each mutation category; SBSs -
single base substitutions). Error bars (black) reflect 95% confidence intervals. d Mutational signatures of temozolomide in glioblastomas with expressed
(top) and epigenetically silenced MGMT (centre) displayed as probability distributions across 104 mutation classes, coloured bars reflect the mean
estimate of the probability of mutation for each mutation class, error bars represent 95% credible intervals. Bottom: mean mutation rate fold changes
per mutation class with 95% confidence intervals, with significant fold changes marked by darker colour (if credible intervals do not cross 1, red
dotted line). Right: Total mutation burden in temozolomide-treated samples with silenced (sil., n= 6) and expressed (exp., n= 11) MGMT. Boxes denote
the interquartile range (IQR, 25–75% percentile), thick lines the median, whiskers - 1.5× the IQR below the first quartile and above the third quartile.
Dots represent mutations in individual samples. MGMT silencing was significant as predictor of burden in a Poisson GLM (burden ~MGMT status,
p value < 10−16).
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NER mends most genotoxic lesions. NER acts by excising a
large variety of damaged bases, preventing up to 90% of
mutations induced by different genotoxins, particularly those
which induce damage to adenine or thymine (Fig. 5a). After
AA exposure, C. elegans xpf-1 mutants showed a 5-fold
increase in mutation rate with a 20-fold increase in the num-
ber of 50–400 bp deletions, confirming that NER is crucial for
the repair of bulky DNA adducts (Fig. 5b). Aristolactam
adducts occur on adenine48, and the failure to excise the
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deletion (1–5, 6–50, 51–400 bp)
T>C
T>G
deletion/insertion (1–50, 51–400 bp)
insertion (1–5, 6–50, 51–400 bp)
Dose [μM]
C>A C>G C>T T>A T>C T>G
Fig. 4 Error-prone TLS induces the majority of mutations observed upon genotoxin exposure. a Estimated mean fractions of mutations caused or
prevented by three C. elegans TLS polymerases (REV-3, POLH-1 and POLQ-1) across genotoxin exposures along with 95% confidence intervals. Bars with
no fill colour reflect non-significant contributions (chi-squared test FDR 5% in each mutation category). Layout as in Fig. 3c. b Aristolochic acid-induced
signatures in wild-type and TLS polymerases η (polh-1) and θ (polq-1) deficient C. elegans. Layout as in Fig. 3b. c Interactions of APOBEC-induced DNA
damage with deficiency in human REV1- or UNG-dependent BER. APOBEC mutational signatures of base substitutions in REV1 and UNG wild-type (top) and
deficient (centre) samples and signature fold changes per mutation class (bottom). Layout as in Fig. 3d. Right: Observed difference between the fractions of
C > G and C > T mutations in a TCN context in samples with (mut) and without (wt) REV1 or UNG defects with sample sizes indicated in parentheses.
Boxes denote the interquartile range (IQR, 25–75% percentile), thick lines the median, whiskers 1.5× the IQR below the first quartile and above the third
quartile. Grey dots represent data from individual samples. Difference in the fraction of C > T mutations was significant between classes as assessed by a
two-sided binomial test (p value ~5 × 10−7).
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In contrast to previous reports on the lack of recognition of the
aristolactam adducts by global genome NER (GG-NER)49, xpc-
1 mutants (which are defective for GG-NER) showed increased
numbers of mutations upon AA exposure, especially deletions
of 50–400 bps, similar to xpf-1 mutants which are deficient in
both GG-NER and transcription coupled NER (TC-NER)
(Supplementary Fig. 6a). Interestingly, only xpf-1 (which is
defective for both TC-NER and GG-NER) but not xpc-1 defi-
ciency led to an increase in the number of C > A mutations,
suggesting that TC-NER maybe be more crucial to the repair of
dG aristolactam adducts, which tend to be mispaired with
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In contrast to the previous examples in which DNA repair
deficiencies changed the mutational spectra induced by mutagens,
knockouts of the NER genes xpf-1 and xpc-1 did not alter
mutation spectra but uniformly increased the rate of UV-B
induced mutagenesis by a factor of 20 and 32, respectively
(Fig. 2a, Supplementary Fig. 6b). This uniform increase indicates
that NER is involved in repairing the majority of mutagenic UV-
B DNA damage including both single- and multi-nucleotide
lesions. Interestingly, xpf-1 and xpa-1 knockouts also uniformly
increased the mutation burden resulting from EMS and MMS
alkylation by a factor of 2, indicating that NER also contributes to
error-free repair of alkylation damage (Supplementary Fig. 4).
Further cases of genotoxin signatures being changed in NER
mutants were observed following ionizing radiation and cisplatin
exposure (Fig. 5c, Supplementary Fig. 6c). In IR treated samples,
xpa-1 deficiency led to a 10-fold increase in C > T changes as well
as MNVs. Upon cisplatin exposure, NER defects increased the
amount of C > A and T > A mutations, as well as dinucleotide
substitutions likely introduced during the bypass of cisplatin-
induced crosslinks50,51. In addition, in the fan-1 mutant, defective
for a conserved nuclease involved in ICL repair, cisplatin
exposure led to a dramatic elevation of 50–400 base deletions
without affecting base substitutions (Supplementary Fig. 6c).
In humans, xeroderma pigmentosum (XP), a hereditary
syndrome characterised by an extreme sensitivity to UV exposure
and high risk of skin and brain cancers during childhood, is often
associated with biallelic inactivation of NER52. Investigating the
changes in the UV signature between 8 adult skin tumours and 5
tumours from XPC defective XP patients53, we observed a relatively
uniform 30-fold change in mutation rate per year in XP patients
across base substitution types in line with findings in C. elegans
(Fig. 5d). Moreover, there was a mild shift in certain base contexts,
with nearly 3 times more mutations acquired in NpCpT, but also
TpCpD context (D=A/G/T). XPC deficiency inactivates GG-NER,
which is possibly compensated by transcription coupled NER53. It is
thus possible that this shift in mutation spectrum reflects a sequence
specificity of GG-NER repair efficiency.
Notably no effects were observed for NER variants in sporadic
lung and skin cancers, although one might expect NER involvement
in repairing bulky DNA adducts generated from tobacco smoke and
UV light (Supplementary Fig. 3e–g). Of note ERCC2/XPD NER
mutations are also relevant in urothelial cancers, where they have
been reported to produce a mild increase in the number of
mutations attributed to COSMIC signature 554.
Discussion
Taken together, our experimental screen and data analysis show
that mutagenesis is fundamentally driven by the counteraction of
DNA damage and repair. A consequence of this interplay is that
the resulting mutation rates and signatures vary in a number of
ways. The systematic nature of the screen with multiple known
doses of different genotoxins applied across a broad range of
genetic backgrounds enabled us to precisely characterise how
mutation patterns of genotoxic treatments change under con-
comitant DNA repair deficiency.
Uniform mutation rate increases, without a change of muta-
tional signature, suggest that a repair gene or pathway is involved
in repairing all DNA lesions generated by the genotoxin. Exam-
ples of such interactions are NER deficiency combined with the
exposure to UV-B damage, bulky DNA adducts, and alkylating
agents. Conversely, mutational signatures change if divergent
repair pathways are involved in repairing specific subsets of DNA
lesions introduced by the same genotoxin. We illustrated this for
alkylating agents, with the same adducts at different bases and
residues being repaired by distinct pathways. In the case of DNA
methylation, our data corroborate the notion that the muta-
genicity of O6-methylguanine stems from mis-pairing with thy-
mine, and is repaired by O6-alkylguanine DNA alkyltransferases,
while N3-methyladenine stalls replication, which is resolved by
TLS polymerases Pol κ and Rev-3/Pol ζ.
Our screen revealed that TLS plays an important and varied
role in mutagenesis: perhaps counterintuitively, error-prone TLS
by Pol η (POLH-1) and ζ (REV-3) was found to cause the
majority of base substitutions resulting from bulky adducts,
alkylated bases, UV-B-induced damage and to a small extent
cisplatin. Thus, knockouts of rev-3 and polh-1 resulted in reduced
base substitution rates, but increased rates of large deletions and
SVs, presumably due to replication stalling and fork collapse in
the absence of TLS. Conversely, polymerase κ (POLK-1) was
found to prevent up to 99% of mutations induced by DNA
alkylation, by performing largely error-free TLS across N3-meA
and N3-etA. Lastly, Pol θ (POLQ-1) mediated deletions observed
upon genotoxic exposures such as AA provide a repair
mechanism (TMEJ) for replication-associated DSBs19. These
findings imply that TLS—rather than the primary mutagenicity of
genotoxic lesions—is an essential component of mutagenesis, and
suggest a direction for further exploration in human tissue culture
experiments.
With the exception of known hypermutator conditions, the
association of mutations in DNA repair genes and mutational
signatures in human cancer data proves challenging, due to the
unknown dose of mutagene exposure and the unknown timing of
both mutagen exposure and repair deficiency. The association is
further complicated realising that many of the experimental
genotoxin repair interactions described here had a moderate
magnitude. Finally, while non-silent mutations in DNA repair
genes are common, we found that bi-allelic inactivation of both
copies generally required for loss of function is rare (Supple-
mentary Note 3).
Yet to appreciate the implications of our experimental results
for cancer development, it is worth reflecting on the fact that all
human cells are subject to continuous, lifelong exposures to a
variety of cell intrinsic and exogenous mutagenic processes55.
Cancer is driven by this cumulative and lifelong action of
mutational processes, which each incrementally add to cancer
risk. Even more so, cancer transformation requires between 2 and
Fig. 5 Nucleotide excision repair contributes to the repair of various genotoxin-induced damage. a Estimated mean fractions of mutations contributed
and prevented by different NER components for various genotoxin treatments along with 95% confidence intervals. Bars with no fill colour reflect non-
significant contributions (chi-squared test FDR 5% in each mutation category). Layout as described in Fig. 3c. b Signatures of aristolochic acid exposure in
wild-type and xpf-1 NER deficient C. elegans. Layout as described in Fig. 3b. xpf-1 deficiency leads to a 10-fold increase in small deletions compared to the
values expected without interaction. Note that scale bars are different between wild-type (WT) and xpf-1−/− panels. c Signatures of γ-radiation in wild-type
and xpa-1 NER deficient C. elegans. Layout as described in Fig. 3b. xpa-1 deficiency leads to a 2-fold overall increase in mutations, including a 5-fold increase
in TCN > TTN changes and dinucleotide substitutions compared to the values expected without interaction. d Mutational signature of UV light in skin
cutaneous squamous cell carcinoma (cSCC) samples from patients with functional (top panel) and mutated XPC (XP patients, central panel) expressed in
mutations per year, and fold changes per mutation class (bottom panel). Note that scale bars are different between panels of XPC+/+ and XPC−/−
tumours with on average 30× more mutations in GG-NER deficient tumours.
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10 driver gene point mutations56, and therefore the relation
between mutation rate and cancer development is not linear but
polynomial, implying that even small changes in mutation rate
exert large cancer-promoting effects57.
The fact that moderate changes in lifetime mutation burden
cause large increases in cancer risk can be appreciated for a
range of cancer predisposition syndromes, and smoking-related
lung cancers (Fig. 6). While MMR-deficient colorectal cancers
have an ~8–10-fold higher mutation burden than MMR-
proficient carcinomas, inherited MMR deficiency increases
colorectal cancer risk >115-fold57. Similarly, while HR-deficient
breast cancers only display a ~3-fold higher mutation burden,
this correlates with a 20–40-fold increased cancer risk for car-
riers of BRCA1/2 mutations58. Even more so, XP patients dis-
play a 30-fold increased mutation rate53, but have an
approximately 10,000-fold increased rate of skin cancers52. An
implication of these data and models is that even fairly small
changes in mutation rates have a large impact on cancer risk,
and conversely noticeable risk factors may derive from rather
moderate mutagenic effects. These findings offer an explanation
why genes with no overt detectable mutator phenotype may be
positively selected in cancers (Supplementary Fig. 3h, Supple-
mentary Note 3). Furthermore, they underscore the need to
accurately determine seemingly small and subtle mutagenic
effects, which are challenging to detect in cancer genomes, but
are often found in our experimental screen (Fig. 2a, b).
The analysis of mutational signatures derived from cancer
genomes has gained much attention in recent years and drama-
tically deepened our understanding of the range and common
types of mutation patterns observed in human cancer and normal
tissues. However, our study suggests that not all genotoxins or
DNA repair deficiencies yield unique mutational signatures due
to mutual interactions, or simply manifest as an increased rate
without a change in mutational signature as in the case of NER
deficiency. It thus appears important to recognise the variable
nature of mutagenesis due to the eternal struggle between DNA
damage and repair. The high efficiency and redundancy of DNA
repair processes removes a large fraction of genotoxic lesions and
only damage left unrepaired results in mutations—either directly
by mispairing or indirectly through error prone repair and tol-
erance mechanisms such as TLS. Mutation patterns observed in
normal and cancer genomes represent the joint product of DNA
damage, repair and tolerance.
Methods
Experimental design. C. elegans strains backcrossed 6× against the wild-type
reference TG181315 and mutagen doses are described in Supplementary Table 1.
Mutation accumulation experiments. For mutation accumulation experiments
5–10 single L4 stage hermaphrodites (F1s) were randomly chosen from wild-type
as well as each mutant (P0, 6× backcrossed against wild-type) and transferred to
individual 1× NGM plates seeded with OP50 bacteria. Every 3–4 days, 1 single L4
hermaphrodite was randomly chosen among the progeny per plate and propagated
further, a process repeated until the indicated generation (F5, F20 and F40). The
final generation was then starved and used for DNA isolation and glycerol stocks.
For each genotype, the P0 or F1 generation plate and at least three plates of the
final generation lines were chunked to 9 cm 3× NGM plates and allowed to reach
starvation. Worms were then washed off plates, washed 3× in M9 medium, pelleted
and frozen in liquid nitrogen, before DNA extraction (below).
Genotoxin treatment. Gravid adult worm populations were washed off 1× NGM
plates with M9 medium, pelleted by centrifugation for 2 min at 400 × g, and washed
with M9 to remove bacteria. Pelleted worms were then bleached and the released
eggs resuspended and washed 3 times in M9 medium. Eggs were left in M9 for 24 h
under gentle shaking to permit hatching and synchronisation at early L1 stage and
were then transferred to OP50-seeded NGM plates. Once the population reached the
young adult stage, 20 worms were picked for each genotype and genotoxin dose and
incubated for 16 h at 20 °C in OP50-containing M9 medium with the desired con-
centration of EMS, DMS, MMS, aflatoxin B1 and AA. After the incubation, worms
were centrifuged, transferred to OP50-seeded NGM plates and allowed to recover for
24 h. For cisplatin, mechlorethamine, and mitomycin C treatment 15–20 L4s were
picked per genotype and genotoxin dose and were transferred as 24 h post L4 stage
adults into OP50-containing M9 medium containing the indicated genotoxin con-
centrations. Genotoxins were diluted from freshly prepared stock solutions. Incu-
bation was performed for 16 h at 20 °C under the hood in a shaking incubator.
Worms were then transferred and left to recover for 24 h on OP50-seeded NGM
plates. For X-ray exposure 15–20 L4 larvae were picked into M9 medium per gen-
otype and dose. Irradiation was performed with the indicated radiation doses using a
low energy photon radiosurgery system X-ray source. Worms were then transferred
and allowed to recover for 24 h on OP50-seeded NGM plates. For γ-ray exposure
15–20 L4 larvae were picked onto OP50-containing NGM plates per genotype and
dose. Worms were irradiated with the indicated radiation doses using a 137Cs source
(2.14 Gymin−1, IBL 437C, CIS Bio International) and allowed to recover for 24 h.
For UV treatment, early L1s, obtained after bleaching and synchronisation, were
transferred to OP50-seeded NGM plates and irradiated at the indicated UV dose, in
triplicate. Once grown to the young adult stage, 3 × 3 worms per genotype and dose
were transferred to a fresh plate for progeny viability testing and propagation. For
HU-treatments ~100 L1s were placed onto HU-containing OP50-seeded NGM
plates and allowed to grow for 57 h. Worms were then transferred to new plates
without HU and allowed to recover for 15 h.
Progeny viability scoring and F1 isolation. Following genotoxin treatment and
recovery 3× three worms/genotype and dose were transferred to new plates and
allowed to lay eggs for 6 h. Adults were then removed. To determine progeny
viability, the number of eggs laid as well as the number of unhatched eggs after 24 h
was counted. The percentage of hatched eggs compared to the total number of eggs
laid was calculated for each plate, and the mean and SD of each technical triplicate
calculated. A minimum of three independent experiments (biological triplicate)
was performed for each genotoxin. To obtain F1 lines for DNA sequencing, two F1
L4 larvae were picked from each of the three plates for each genotype and dose,
transferred individually to a fresh plate and allowed to proliferate. These duplicates
enhanced the probability to obtain one fertile line from each plate especially from
animals treated with high genotoxin doses. From each duplicate, one line was
selected for expansion (see MA experiment above), genomic DNA extraction and
sequencing. The zygotes which lead to the F1 generation provide a single cell
bottleneck where mutations of exposed male and female germ cells are fixed before
being clonally amplified during C. elegans development and passed on to the next
generation in a mendelian ratio.
DNA extraction. Genomic DNA was isolated from frozen samples using Char-
geSwitch® gDNA Mini Tissue Kit (Invitrogen) following manufacturers instruc-
tions albeit with Proteinase K incubation O/N.
























Fig. 6 DNA repair deficiency drives cancer evolution. Relationship
between relative cancer risk and point mutation rate change for different
DNA repair pathway gene mutations. Black lines depict the expected power
law depency in an evolutionary model with different numbers (from n= 2
to n= 10) of driver gene mutations57. Coloured boxes represent the ranges
of incidence and mutation rate fold changes for indicated combination of
cancer type and DNA repair deficiency or exposure. The grey shaded area
denotes the range of less than 2-fold increase in mutation rate typically
observed in our experimental screen, which may correspond to up to 10-
fold increase in cancer incidence.
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Data acquisition. C. elegans genomic DNA was sequenced using Illumina HiSeq
2000 and X10 short read sequencing platforms at 100 bp paired-end reads with a
mean coverage of 50×. Raw sequencing reads were aligned to the C. elegans
reference genome (WBcel235/ce11 build) using BWA algorithm59. TCGA human
cancer data was taken from NCI GDC (https://gdc.cancer.gov60), and respective
studies34,61–66.
Mutation calling, filtering, and classification. C. elegans aligned sequence reads
were processed through the Sanger Cancer IT pipeline using CaVEMan for SNV
calling67, Pindel for indel calling68, and DELLY69 for SV identification. Filtering of
samples was performed using the same criteria as in ref. 9. Base substitutions were
called using CAVEMAN67 with the following filtering criteria:
1. Coverage of the variant site in both the sample of interest (test sample) and
reference (untreated F0 wild-type sample) did not exceed 150 reads or
recede below 15 reads.
2. No reads reported the variant in the reference sample.
3. At least 20% of reads and at least 5 reads reporting the variants in test
sample.
4. At least one read in the test sample reporting the variant in each read
direction.
5. No indel was called at the same position (relevant for homopolymer
junctions).
All variants were filtered against the normal panel of six untreated F1 wild-type
samples to remove recurrent technical errors. Propagated samples (of generation >
F1) of the same genotype from mutation accumulation experiments were not
compared to each other to avoid overfiltering of related samples (e.g. when F40
lines were derived from the same F20 lines sequenced in the same study). Multiple
substitutions which were found at adjacent sites in the same sample were classified
as dinucleotide or MNVs, if their variant allele frequencies were similar (difference
less than 5%). Overall, base substitutions were classified into 96 SNV classes (6 base
substitution types per 16 trinucleotide contexts) and 2 MNV classes (dinucleotide
variants and variants longer than 2 bp).
Small size insertions and deletions (1–400 bp) were called using PINDEL68 with
the following filter criteria:
1. Coverage of the variant site in both the sample of interest and reference did
not exceed 150 reads or recede below 10 reads.
2. No more than 1 read reporting the variant in the reference sample.
3. More than 20% of reads and at least 5 reads reporting the variants in test
sample.
4. At least one read in test sample reporting the variant in each direction.
5. If the variant falls into a repetitive region, the region should not exceed 18
repeats.
All variants were filtered against the normal panel of six wild-type samples;
samples of the same genotype and generation higher than one were not compared
to each other to avoid overfiltering of related samples. Indels were classified into 14
classes based on indel type (deletions, insertions, and complex indels—named
deletions-insertions (DI)), size (1, 2–5, 5–50 and 50–400 bp), and presence in
repetitive or non-repetitive sequence contexts.
SVs were called using DELLY69 with the following filters:
1. Each variant was supported by more than ten high-quality reads in test
sample and no reads were present in the reference sample.
2. Variant passed the default DELLY quality filter (paired-end support <5 for
translocations or <3 for other SVs, or mapping quality <20).
3. Variants in telomeric regions were removed.
4. Duplicated SVs across unrelated samples were removed. Samples of the
same genotype and generation higher than 1 were not compared to each
other to avoid overfiltering of related samples.
The resulting sets of breakpoints for each sample were further classified in line
with ref. 70 using clustering by proximity and simplified into a set of seven SVs:
tandem duplications, deletions, inversions, intrachromosomal translocations,
interchromosomal events, foldbacks (change of the orientation of sequence without
a second breakpoint in close proximity) and complex variants (not falling in any of
the previously described categories). Stand-alone deletions and tandem
duplications were additionally tested for reliability by comparing the ratios of the
coverages between the test and control samples outside the variant breakpoints and
between them, to ensure that there is a drop in coverage for a deletion and an
increase for a duplication.
Handling of variant calling results, filtering and classification were performed
using R package VariantAnnotation-1.28.1071. Bam file statistics necessary to
perform coverage comparison within and outside of deletions and tandem
duplications was performed using samtools-0.1.1872. Mutation counts for all
samples are listed in Supplementary Data 1. Data visualisation was performed
using t-SNE73 based on the cosine distance of the 119-dimensional mutation
spectra, averaged across replicates.
Extraction of interaction effects from experimental data. For each sample i= 1,
…, 2717 and mutation class j= 1, …, 119, we counted the respective number of
mutations per sample Yij. Using matrix notation, the counts Y 2 N2717 ´ 1190 (where
N0 means the set of natural numbers and zero) were modelled by a negative
binomial distribution
Y  NBðμ; φ ¼ 100Þ;
with scalar overdispersion parameter φ= 100 selected based on the estimates of
overdispersion in the dataset, and matrix-variate expectation μ 2 R2717 ´ 119þ0 , where
Rþ0 ¼ Rþ ∪ f0g.
The basic structure of the expectation is
μ ¼ μG gþ αIð Þ þ dμM  βI ; ð1Þ
where g ∙ μG 2 R2717 ´ 119þ0 describes the expected mutations just due to the sample’s
genotype in the absence of a genotoxin after N 2 Z2717 ´ 10 generations. The vector g
2 R2717 ´ 1þ0 denotes the generation number in every sample,








1j , k= 1, …, 2717, adjusted for the
chances of fixation after Nk generations given the 25–50–25% probability of each
mutation becoming homozygous, remaining heterozygous or being lost in each
generation.
The matrix d ∙ μM 2 R2717 ´ 119þ0 denotes the expected mutation counts induced
by mutagens at doses d 2 R2717 ´ 1þ0 in wild-type conditions. The terms αI 2 R2717 ´ 1þ0
and βI 2 R2717 ´ 119þ model how these terms interact (more details follow below).
Here, the dot product ‘∙’ is element-wise and we use the convention that a
dimension of length 1 is extended by replication to match the length of the
corresponding dimension of other factors in the product.
The expected number of mutations induced by genotypes, μG, has the structure
μG ¼ G ´ SG; ð2Þ
where G 2 Z2717 ´ 542 is the binary indicator matrix for denoting which one of the 54
genotypes a given sample has (Gij = 1 if sample i has genotype j, otherwise Gij = 0).
The matrix
SG 2 R54 ´ 119þ denotes the mutation spectrum (i.e. signature) across the 119
mutation classes for each of the 54 genotypes in the absence of genotoxic
exposures. To provide a more stable estimate for genotype signature, the prior
distribution for SG is derived from SG*= SG | YMA, where YMA 2 Z474 ´ 1190 is the
matrix of counts coming from mutation accumulation samples only, and SG* has a
log-normal prior distribution SG* ~logN(0, σG2) iid with a scalar variance σG2.
Thus, we obtained priors for 51 genotypes. agt-1, exo-1 and rad-51 mutant strains
did not have MA experiments, so they were assigned with SN2*, wild-type prior.
The prior for SG was defined as SG ~ Г(shapeG, rateG), where the matrix
parameters shapeG, rateG were fitted to the posterior draws for SG*.
Similarly, the expected mutations contributed by mutagens at their unit doses,
μM, reads
μM ¼ M ´ SM; ð3Þ
with M 2 Z2717´ 122 being the indicator for the 12 mutagens (including Mitomycin
C, which was eventually not used in the interaction experiments) and SM 2 R12´ 119þ
being their signatures in wild-type, with per-column prior SM(j) ~logN(0, σMj2), j =
1,… 12, where the variances σM2= (σM12,…, σM122) have prior distributions σMj2 ~
Г(1, 1) iid.
Thus, using the definitions (2) and (3), the matrix-variate expected number of
mutations from (1) can be written as
μ ¼ ðgþ αIÞ  G ´ SGð Þ þ d  βI  M ´ SMð Þ: ð4Þ
The vector-variate interaction term αI measures how the mutations expected for
genotypes G may uniformly increase under mutagen exposure and is taken to be
linear with respect to the mutagen dose
αI ¼ d  I ´ bIð Þ þ ε; ð5Þ
The symbol I 2 Z2717 ´ 1962 is the binary indicator matrix for each one of the 196
interactions tested in the screen multiplied by the interaction rate bI 2 R196 ´ 1þ ,
which measures how much the mutational signature of the genetic background
increases upon genotoxic exposure with dose d. The interaction term is modelled to
have a prior exponential distribution bI ~ Exp(1) iid.
Lastly, ε is a random offset to allow for a possible divergence of the genotypes
between experiments, adding ε ∙ μG mutations with the same spectrum as in the
absence of a mutagen in a dosage-independent fashion. The random offset is
modelled as ε= (J × aJ), where J 2 Z2717 ´ 2082 is an extended binary indicator
matrix for each one the 196 interactions and 12 wild-type exposure experiments,
with value aJ 2 R2717 ´ 1þ0 , aJ ~Exp(1) iid.
In addition to this scalar interaction, the wild-type spectrum of the mutagen SM
may change by the factors βI 2 R2717 ´ 119þ measuring the FC of each mutation class
which is expressed as
βI ¼ expðI ´ SIÞ; ð6Þ
where SI 2 R196 ´ 119 is the FC for each mutation class in a given interaction.
The prior distributions for each of the 119 subclasses of mutations in SI are
calculated in groups of 11 main mutation categories (6 types of SNVs, MNVs, 3
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types of indels, SVs), since the numbers for individual mutation classes were
sometimes very small. The prior was defined using SI 2 R196 ´ 11 from an analogous
model as described above, but applied only to observed mutation counts summed
into 11 main mutation categories Y 2 N2717 ´ 110 . We used a Laplace prior S(j)I
~Laplace(0, σ2Ij), j= 1, …, 196, first to calculate SI|Y. The posterior expected value
SI*= E[SI|Y] was chosen as the prior expectation for the 119-dimensional
mutation effects SI, SI(j) ~ Laplace(SI* × C, σIj2), j = 1, …, 196, where C is the
matrix spreading mutation category value across the corresponding individual
mutation classes, and the variances σI2= (σI12,…, σI1962) and σI2= (σI12,…, σI1962)
were assumed to come from Γ 1; 1ð Þ iid.
Bayesian estimates of the parameters SG, SM, SI, aJ, bI and hyperparameters σI2,
σM2 were calculated via Hamiltonian Monte Carlo sampling using the ‘greta’ R
package (http://CRAN.R-project.org/package=greta) (Supplementary Methods).
We used 2000 steps for warmup and 5000 steps over 4 chains to ensure
convergence. Mean estimates along with their 95% credible intervals may be found
in Supplementary Data 2 and 3.
Combined genotype-mutagen interactions were tested for effect in two settings:
altering the total number of base substitutions, and changing the distribution of
mutations. The FC in the number of single base substitutions was calculated as
predicted with interactions versus the one predicted without interactions using
2000 out of 10,000 draws across 4 chains for all 196 interactions. The change in
spectrum was quantified by calculating the cosine distance between the expected
profiles with and without interactions, and those with distance higher than 0.2 were
considered different. As all of the interactions which showed a change in signature
appearance also came up in burden analysis, we only applied hypothesis testing (by
testing the χ2-statistic of the squared z-score of log(E[FCs]), s= 1, …, 196), and
corrected for multiple testing using Benjamini–Hochberg FDR control procedure.
Batch effect control for EMS exposure. EMS exposure was the only genotoxin for
which we observed very different mutation counts across different experiments in
wild-type. Respective samples were coming from 5 batches, which are stated in the
‘Comments’ section of the samples description table in Supplementary Table 1. In
order to account for this effect, we introduced additional factor ξ, ξ= {ξi}, i= 1, …,
4 which accounted for the log-difference in real dose applied to the samples in
batches 2 to 5 compared to batch 1 which was considered as reference. The prior
distribution for these adjustments was taken as ξi ~N(0, 0.5) iid. The dose for these
samples was then calculated as d’= d ∙ exp(batch × ξ), where batch 2 Z2717 ´ 42 is a
binary matrix reflecting if a sample belongs to any of the batches 2–5. These
adjustments were estimated along with the rest of the coefficients.
Estimation of mutational contributions of DNA repair components. Subsequent
estimates of the fraction of mutations contributed or prevented by different DNA
repair components upon genotoxin exposures were acquired as 1 1x
   100% for
positive interactions and as 1 xð Þ  100% for negative interactions, where x is the
FC in the mutation rate induced by the respective interaction compared to the
exposure in wild-type.
TCGA/PCAWG human cancer data analysis. The susceptibility of a DNA
pathway to alteration was defined as having altered expression or high impact
mutations in relevant genes (Supplementary Methods, Supplementary Data 3). The
interaction effect was then estimated using Hamiltonian Monte Carlo sampling74
for the following model for matrix of mutation counts in N samples with R
mutation classes Y 2 NR ´N0
Y  NBðμ; φÞ;
μ ¼ SðKÞ ´ αðKÞ þ ðSðKÞ ´ αðKÞÞ  fG;
fG ¼ expðX ´ βÞ;
α  Unif 0;Mð ÞK ´N;
β  N 0; 0:5ð ÞM ´R;
where α is the matrix of exposures (number of mutations assigned to each sig-
nature), S is a R × K matrix of K signatures (each column is a signature, and is
normalised to sum to 1), and fG is a R ×N matrix of interaction factors which alter
the signature. It consists of X 2 ZN ´M2 —a binary matrix of labels, and β which is a
M × R matrix of spectra of the interaction effects with a i.i.d. N(0, 0.5) prior. M is
the maximal number of mutations per sample in the dataset. The overdispersion
parameter φ= 50 was chosen based on variability estimates across all cancer
samples. For details on sample selection, analysis of expression, mutations and
selective pressure across DNA repair genes, see Supplementary Methods, Supple-
mentary Notes 3 and 4 and Supplementary Data 3 and 5.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequencing data are available under ENA Study Accession Numbers ERP000975 [https://
www.ebi.ac.uk/ena/data/search?query=ERP000975] and ERP004086 [https://www.ebi.ac.
uk/ena/data/search?query=ERP004086]. Mutation counts underlying the plots shown in
Figs. 1a, b, 3b, 4b, 5b, c, Supplementary Figs. 4a, b, 5a, b, 6a, b are provided as
Supplementary Data 1. Signature and interaction-related fold change estimates from the
model (used in Figs. 1c, d, 2, 3b, 4b, 5b, c, Supplementary Figs. 2, 4–8) are supplied as
Supplementary Data 2 and 4. Filtered VCF files for each sample are available in
Supplementary Data 6. Annotated Mutect somatic variant calls, gene expression and
DNA methylation data for TCGA samples are publicly available from NCI GDC (https://
gdc.cancer.gov60) and supplementary materials from the respective studies34,62–66. A set
of more accurately filtered SNV and indel calls for TCGA samples used for mutational
signature analysis were used56. Please refer to Supplementary Table 2 for the links to all
sources used for human data analysis. For more details on sample selection, see
Supplementary Methods. Whole genome sequencing data of cSCCs from XP and non-XP
patients53 is stored in dbGaP database as controlled access data under accession code
phs000830.v1.p1 [https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?
study_id=phs000830.v1.p1]. The remaining data are available in the Article,
Supplementary files or available from the author upon reasonable request.
Code availability
Codes for most downstream analyses and figures can be accessed from http://github.
com/gerstung-lab/signature-interactions. Raw data processing and variant calling was
performed via Sanger Institute Cancer IT pipeline using bwa v. 0.5.9, samtools v. 0.1.18,
CaVEMan v. 1.5.3, PINDEL v. 0.3.5, DELLY v. 0.7.859,67–69,72.
Received: 24 February 2020; Accepted: 26 March 2020;
References
1. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer.
Nature 500, 415–421 (2013).
2. Alexandrov, L. B. et al. The repertoire of mutational signatures in human
cancer. Nature 578, 94–101 (2020).
3. Helleday, T., Eshtad, S. & Nik-Zainal, S. Mechanisms underlying mutational
signatures in human cancers. Nat. Rev. Genet. 15, 585–598 (2014).
4. Poon, S. L. et al. Genome-wide mutational signatures of aristolochic acid and
its application as a screening tool. Sci. Transl. Med. 5 197ra101 (2013).
5. Alexandrov, L. B. et al. Mutational signatures associated with tobacco smoking
in human cancer. Science 354, 618–622 (2016).
6. Drost, J. et al. Use of CRISPR-modified human stem cell organoids to study
the origin of mutational signatures in cancer. Science 358, 234–238 (2017).
7. Pilati, C. et al. Mutational signature analysis identifies MUTYH deficiency
in colorectal cancers and adrenocortical carcinomas. J. Pathol. 242, 10–15
(2017).
8. Haradhvala, N. J. et al. Distinct mutational signatures characterize concurrent
loss of polymerase proofreading and mismatch repair. Nat. Commun. 9, 1746
(2018).
9. Meier, B. et al. Mutational signatures of DNA mismatch repair deficiency in C.
elegans and human cancers. Genome Res. 28, 666–675 (2018).
10. Bertolini, S., Wang, B., Meier, B., Hong, Y. & Gartner, A. Caenorhabditis
elegans BUB-3 and SAN-1/MAD3 spindle assembly checkpoint components
are required for genome stability in response to treatment with ionizing
radiation. G3 7, 3875–3885 (2017).
11. Boulton, S. J. et al. Combined functional genomic maps of the C. elegans DNA
damage response. Science 295, 127–131 (2002).
12. Lans, H. & Vermeulen, W. Nucleotide excision repair in Caenorhabditis
elegans. Mol. Biol. Int. 2011, 1–12 (2011).
13. Arvanitis, M., Li, D.-D., Lee, K. & Mylonakis, E. Apoptosis in C. elegans:
lessons for cancer and immunity. Front. Cell. Infect. Microbiol. 3, 67 (2013).
14. Tijsterman, M., Pothof, J. & Plasterk, R. H. A. Frequent germline mutations
and somatic repeat instability in DNA mismatch-repair-deficient
Caenorhabditis elegans. Genetics 161, 651–660 (2002).
15. Meier, B. et al. C. elegans whole-genome sequencing reveals mutational
signatures related to carcinogens and DNA repair deficiency. Genome Res. 24,
1624–1636 (2014).
16. Denver, D. R. et al. A genome-wide view of Caenorhabditis elegans base-
substitution mutation processes. Proc. Natl Acad. Sci. USA 106, 16310–16314
(2009).
17. Zhao, H. et al. Mismatch repair deficiency endows tumors with a unique
mutation signature and sensitivity to DNA double-strand breaks. Elife 3,
e02725 (2014).
18. Davies, H. et al. HRDetect is a predictor of BRCA1 and BRCA2 deficiency
based on mutational signatures. Nat. Med. 23, 517–525 (2017).
19. Roerink, S. F., van Schendel, R. & Tijsterman, M. Polymerase theta-mediated
end joining of replication-associated DNA breaks in C. elegans. Genome Res.
24, 954–962 (2014).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15912-7 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:2169 | https://doi.org/10.1038/s41467-020-15912-7 |www.nature.com/naturecommunications 13
20. Northam, M. R., Robinson, H. A., Kochenova, O. V. & Shcherbakova, P. V.
Participation of DNA polymerase ζ in replication of undamaged DNA in
Saccharomyces cerevisiae. Genetics 184, 27–42 (2010).
21. Lange, S. S., Wittschieben, J. P. & Wood, R. D. DNA polymerase zeta is
required for proliferation of normal mammalian cells. Nucleic Acids Res. 40,
4473–4482 (2012).
22. Kucab, J. E. et al. A compendium of mutational signatures of environmental
agents. Cell 177, 821–836.e16 (2019).
23. Huang, M. N. et al. Genome-scale mutational signatures of aflatoxin in cells,
mice, and human tumors. Genome Res. 27, 1475–1486 (2017).
24. Hartman, P. S., Hevelone, J., Dwarakanath, V. & Mitchell, D. L. Excision
repair of UV radiation-induced DNA damage in Caenorhabditis elegans.
Genetics 122, 379–385 (1989).
25. Behjati, S. et al. Mutational signatures of ionizing radiation in second
malignancies. Nat. Commun. 7, 12605 (2016).
26. Szikriszt, B. et al. A comprehensive survey of the mutagenic impact of
common cancer cytotoxics. Genome Biol. 17, 99 (2016).
27. Boot, A. et al. In-depth characterization of the cisplatin mutational signature
in human cell lines and in esophageal and liver tumors. Genome Res. 28,
654–665 (2018).
28. Beranek, D. T. Distribution of methyl and ethyl adducts following alkylation
with monofunctional alkylating agents. Mutat. Res. 231, 11–30 (1990).
29. Brookes, P. & Lawley, P. D. The reaction of mono- and di-functional
alkylating agents with nucleic acids. Biochem. J. 80, 496–503 (1961).
30. Metz, A. H., Hollis, T. & Eichman, B. F. DNA damage recognition and repair by
3-methyladenine DNA glycosylase I (TAG). EMBO J. 26, 2411–2420 (2007).
31. Monti, P. et al. Nucleotide excision repair defect influences lethality and
mutagenicity induced by Me-lex, a sequence-selectiveN3-adenine methylating
agent in the absence of base excision repair†. Biochemistry 43, 5592–5599 (2004).
32. Yoon, J.-H., Roy Choudhury, J., Park, J., Prakash, S. & Prakash, L. Translesion
synthesis DNA polymerases promote error-free replication through the
minor-groove DNA adduct 3-deaza-3-methyladenine. J. Biol. Chem. 292,
18682–18688 (2017).
33. Taira, K. et al. Distinct pathways for repairing mutagenic lesions induced by
methylating and ethylating agents. Mutagenesis 28, 341–350 (2013).
34. Kim, H. et al. Whole-genome and multisector exome sequencing of primary
and post-treatment glioblastoma reveals patterns of tumor evolution. Genome
Res. 25, 316–327 (2015).
35. Sale, J. E., Lehmann, A. R. & Woodgate, R. Y-family DNA polymerases and
their role in tolerance of cellular DNA damage. Nat. Rev. Mol. Cell Biol. 13,
141–152 (2012).
36. Roerink, S. F., Koole, W., Stapel, L. C., Romeijn, R. J. & Tijsterman, M. A
broad requirement for TLS polymerases η and κ, and interacting sumoylation
and nuclear pore proteins, in lesion bypass during C. elegans embryogenesis.
PLoS Genet. 8, e1002800 (2012).
37. Lawrence, C. W. & Hinkle, D. C. DNA polymerase zeta and the control of DNA
damage induced mutagenesis in eukaryotes. Cancer Surv. 28, 21–31 (1996).
38. Diaz, M. et al. Decreased frequency and highly aberrant spectrum of
ultraviolet-induced mutations in the hprt gene of mouse fibroblasts expressing
antisense RNA to DNA polymerase zeta. Mol. Cancer Res. 1, 836–847 (2003).
39. Li, Z. et al. hREV3 is essential for error-prone translesion synthesis past UV or
benzo[a]pyrene diol epoxide-induced DNA lesions in human fibroblasts.
Mutat. Res. 510, 71–80 (2002).
40. Yoon, J.-H. et al. Error-prone replication through UV lesions by DNA
polymerase θ protects against skin cancers. Cell 176, 1295–1309.e15 (2019).
41. Doles, J. et al. Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes
drug-resistant lung tumors to chemotherapy. Proc. Natl Acad. Sci. USA 107,
20786–20791 (2010).
42. Segovia, R., Shen, Y., Lujan, S. A., Jones, S. J. M. & Stirling, P. C.
Hypermutation signature reveals a slippage and realignment model of
translesion synthesis by Rev3 polymerase in cisplatin-treated yeast. Proc. Natl
Acad. Sci. USA 114, 2663–2668 (2017).
43. Schimmel, J., Kool, H., Schendel, R. & Tijsterman, M. Mutational signatures of
non‐homologous and polymerase theta-mediated end-joining in embryonic
stem cells. EMBO J. 36, 3634–3649 (2017).
44. Wyatt, D. W. et al. Essential roles for polymerase θ-mediated end joining in
the repair of chromosome breaks. Mol. Cell 63, 662–673 (2016).
45. Roberts, S. A. & Gordenin, D. A. Hypermutation in human cancer genomes:
footprints and mechanisms. Nat. Rev. Cancer 14, 786 (2014).
46. Morganella, S. et al. The topography of mutational processes in breast cancer
genomes. Nat. Commun. 7, 11383 (2016).
47. Petljak, M. et al. Characterizing mutational signatures in human cancer cell
lines reveals episodic APOBEC mutagenesis. Cell 176, 1282–1294.e20 (2019).
48. Jelaković, B. et al. Aristolactam-DNA adducts are a biomarker of
environmental exposure to aristolochic acid. Kidney Int. 81, 559–567 (2012).
49. Sidorenko, V. S. et al. Lack of recognition by global-genome nucleotide
excision repair accounts for the high mutagenicity and persistence of
aristolactam-DNA adducts. Nucleic Acids Res. 40, 2494–2505 (2012).
50. Matsuda, T. et al. Error rate and specificity of human and murine DNA
polymerase η. J. Mol. Biol. 312, 335–346 (2001).
51. Lee, Y.-S., Gregory, M. T. & Yang, W. Human Pol ζ purified with accessory
subunits is active in translesion DNA synthesis and complements Pol η in
cisplatin bypass. Proc. Natl Acad. Sci. USA 111, 2954–2959 (2014).
52. Bradford, P. T. et al. Cancer and neurologic degeneration in xeroderma
pigmentosum: long term follow-up characterises the role of DNA repair. J.
Med. Genet. 48, 168–176 (2011).
53. Zheng, C. L. et al. Transcription restores DNA repair to heterochromatin,
determining regional mutation rates in cancer genomes. Cell Rep. 9,
1228–1234 (2014).
54. Kim, J. et al. Somatic ERCC2 mutations are associated with a distinct genomic
signature in urothelial tumors. Nat. Genet. 48, 600–606 (2016).
55. Martincorena, I. & Campbell, P. J. Somatic mutation in cancer and normal
cells. Science 349, 1483–1489 (2015).
56. Martincorena, I. et al. Universal patterns of selection in cancer and somatic
tissues. Cell 171, 1029–1041.e21 (2017).
57. Tomasetti, C., Marchionni, L., Nowak, M. A., Parmigiani, G. & Vogelstein, B.
Only three driver gene mutations are required for the development of lung
and colorectal cancers. Proc. Natl Acad. Sci. USA 112, 118–123 (2015).
58. Antoniou, A. et al. Average risks of breast and ovarian cancer associated with
BRCA1 or BRCA2 mutations detected in case Series unselected for family history:
a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117–1130 (2003).
59. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
60. Grossman, R. L. et al. Toward a shared vision for cancer genomic data. N.
Engl. J. Med. 375, 1109–1112 (2016).
61. Ng, A. W. T. et al. Aristolochic acids and their derivatives are widely implicated in
liver cancers in Taiwan and throughout Asia. Sci. Transl. Med. 9 eaan6446 (2017).
62. Cancer Genome Atlas Network. Genomic Classification of Cutaneous
Melanoma. Cell 161, 1681–1696 (2015).
63. Cancer Genome Atlas Research Network. Comprehensive genomic
characterization of squamous cell lung cancers. Nature 489, 519–525 (2012).
64. Cancer Genome Atlas Research Network. Comprehensive molecular profiling
of lung adenocarcinoma. Nature 511, 543–550 (2014).
65. Cancer Genome Atlas Research Network. et al. Integrated genomic
characterization of endometrial carcinoma. Nature 497, 67–73 (2013).
66. Cancer Genome Atlas Research Network. Comprehensive molecular
characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).
67. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast
cancers. Cell 149, 979–993 (2012).
68. Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern
growth approach to detect break points of large deletions and medium sized
insertions from paired-end short reads. Bioinformatics 25, 2865–2871 (2009).
69. Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end
and split-read analysis. Bioinformatics 28, i333–i339 (2012).
70. Li, Y. et al. Patterns of somatic structural variation in human cancer genomes.
Nature 578, 112–121 (2020).
71. Obenchain, V. et al. VariantAnnotation: a Bioconductor package for exploration
and annotation of genetic variants. Bioinformatics 30, 2076–2078 (2014).
72. Li, H. et al. The Sequence Alignment/Map format and SAMtools.
Bioinformatics 25, 2078–2079 (2009).
73. Maaten, Lvander & Hinton, G. Visualizing data using t-SNE. J. Mach. Learn.
Res. 9, 2579–2605 (2008).
74. Neal, R. M. et al. MCMC using Hamiltonian dynamics. Handb. Markov Chain
Monte Carlo 2, 2 (2011).
Acknowledgements
This work was supported by the Wellcome Trust COMSIG consortium grant RG70175, a
Wellcome Trust Senior Research award (090944/Z/09/Z), a Worldwide Cancer Research
grant (18-0644), and by the Korean Institute for Basic Science (IBS-R022-A1-2019) to
AG. We thank the Mitani Lab funded by the National Bio-Resource Project of the
MEXT, Japan, and the Caenorhabditis Genetics Center funded by the NIH Office of
Research Infrastructure Programs (P40 OD010440) for providing strains. Nadezda
Volkova is a member of Lucy Cavendish College, University of Cambridge. We thank
Nuria Lopez-Bigas for critical comments on the paper.
Author contributions
N.V., B.M., A.G. and M.G. wrote the paper, which was approved by all authors. N.V.
analysed all data with input from B.M. B.M. performed mutation accumulation and
mutagenesis experiments. V.G.H. and S.B. performed mutagenesis experiments. S.G. and
H.V. analysed somatic mutation data. F.A. and I.M. contributed to selection analysis. P.C.
and A.G. conceived the study. A.G. and M.G. supervised the analysis.
Competing interests
The authors declare no competing interests.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15912-7
14 NATURE COMMUNICATIONS |         (2020) 11:2169 | https://doi.org/10.1038/s41467-020-15912-7 | www.nature.com/naturecommunications
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-15912-7.
Correspondence and requests for materials should be addressed to A.G. or M.G.
Peer review information Nature Communications thanks the anonymous reviewers for
their contribution to the peer review of this work. Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15912-7 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:2169 | https://doi.org/10.1038/s41467-020-15912-7 |www.nature.com/naturecommunications 15
